Furthermore, treatment with rapamycin, a drug which inhibits mTORC1 activity, slows or prevents AD in multiple mouse models of AD, and genetic depletion of S6K1, a substrate and effector of mTORC1, is sufficient to improve memory and reduce AD pathology in 3xTg mice39,43–45. This evidence concerns the gene RPS6KB1 and Alzheimer disease.